scholarly journals Folate Receptors’ Expression in Gliomas May Possess Potential Nanoparticle-Based Drug Delivery Opportunities

ACS Omega ◽  
2021 ◽  
Vol 6 (6) ◽  
pp. 4111-4118
Author(s):  
Eva McCord ◽  
Shreya Pawar ◽  
Tejaswi Koneru ◽  
Katyayani Tatiparti ◽  
Samaresh Sau ◽  
...  
2017 ◽  
Vol 5 (3) ◽  
pp. 444-454 ◽  
Author(s):  
Zhigang Xu ◽  
Meili Hou ◽  
Xiaoxiao Shi ◽  
Yong-E. Gao ◽  
Peng Xue ◽  
...  

Self-assembled small molecular prodrug loaded with camptothecin in response to glutathione and folate receptors for combined tumour detection and treatment.


RSC Advances ◽  
2015 ◽  
Vol 5 (101) ◽  
pp. 82711-82716 ◽  
Author(s):  
Yu Dong ◽  
Ruixia Cao ◽  
Yingqi Li ◽  
Zhiqin Wang ◽  
Lin Li ◽  
...  

Relying on the role of folate and folate receptors, NPFD nanoparticles tend to selectively discriminate tumor cells from normal cells and enter the cells by clathrin-dependent and receptor-mediated endocytosis.


2008 ◽  
Vol 5 (3) ◽  
pp. 309-319 ◽  
Author(s):  
Xiaobin Zhao ◽  
Hong Li ◽  
Robert J Lee

2018 ◽  
Vol 37 (2) ◽  
pp. 129-135 ◽  
Author(s):  
Fan-Fan Fu ◽  
Ben-Qing Zhou ◽  
Zhi-Jun Ouyang ◽  
Yi-Lun Wu ◽  
Jing-Yi Zhu ◽  
...  

Molecules ◽  
2022 ◽  
Vol 27 (1) ◽  
pp. 261
Author(s):  
Madeeha Shahzad Lodhi ◽  
Fatima Khalid ◽  
Muhammad Tahir Khan ◽  
Zahoor Qadir Samra ◽  
Shabbir Muhammad ◽  
...  

Therapeutic effects of anticancer medicines can be improved by targeting the specific receptors on cancer cells. Folate receptor (FR) targeting with antibody (Ab) is an effective tool to deliver anticancer drugs to the cancer cell. In this research project, a novel formulation of targeting drug delivery was designed, and its anticancer effects were analyzed. Folic acid-conjugated magnetic nanoparticles (MNPs) were used for the purification of folate receptors through a novel magnetic affinity purification method. Antibodies against the folate receptors and methotrexate (MTX) were developed and characterized with enzyme-linked immunosorbent assay and Western blot. Targeting nanomedicines (MNP-MTX-FR Ab) were synthesized by engineering the MNP with methotrexate and anti-folate receptor antibody (anti-FR Ab). The cytotoxicity of nanomedicines on HeLa cells was analyzed by calculating the % age cell viability. A fluorescent study was performed with HeLa cells and tumor tissue sections to analyze the binding efficacy and intracellular tracking of synthesized nanomedicines. MNP-MTX-FR Ab demonstrated good cytotoxicity along all the nanocomposites, which confirms that the antibody-coated medicine possesses the potential affinity to destroy cancer cells in the targeted drug delivery process. Immunohistochemical approaches and fluorescent study further confirmed their uptake by FRs on the tumor cells’ surface in antibody-mediated endocytosis. The current approach is a useful addition to targeted drug delivery for better management of cancer therapy along with immunotherapy in the future.


2017 ◽  
Vol 106 (12) ◽  
pp. 3413-3420 ◽  
Author(s):  
Jianfeng Guo ◽  
Michele Schlich ◽  
John F. Cryan ◽  
Caitriona M. O'Driscoll

2014 ◽  
pp. 1223 ◽  
Author(s):  
Claudia Marchetti ◽  
Margherita Giorgini ◽  
Caterina De Medici ◽  
Innocenza Palaia ◽  
Roberta Iadarola ◽  
...  

2017 ◽  
Vol Volume 11 ◽  
pp. 1315-1334 ◽  
Author(s):  
Tatiana Slastnikova ◽  
Andrey Rosenkranz ◽  
Yuri Khramtsov ◽  
Tatiana Karyagina ◽  
Sergey Ovechko ◽  
...  

2020 ◽  
Author(s):  
Monika Ruzycka ◽  
Patrycja Kowalik ◽  
Agata Kowalczyk ◽  
Piotr Bujak ◽  
Anna M. Nowicka ◽  
...  

Abstract Background Lung cancer is one of the most frequently diagnosed cancer all over the world and a leading cancer-related mortality. The therapy of lung cancer includes surgery, chemotherapy and radiatherapy and mailny depends on the type and stage of lung cancer characterized based on WHO guidelines. Althought the conventional chemotherapy is the main treatment option for small cell lung cancer (SCLC) and a common treatment for non-SCLC it is characterized with lack of specificity resulting to severe toxicities of normal cells and harmful side effects. Therefore, targeted drug delivery (TDD) systems have been used to reduce the systemic toxicity of some conventional chemotherapies in lung cancer. Quantum dots (QDs) are fascinating nanoscale crystals that can serve as nanocarriers in TDD due to their unique physicochemical properties. Therefore, in this paper, the as-desiged QDs, Ag-In-Zn-S-based nanoconjugates for selective doxorubicin (DOX) targeting to lung cancer cells were developed. The QD nanocrystals were modified with 11-mercaptoundecanoic acid (MUA), L-cysteine (Cys) and lipoic acid (LA) used as drug carriers for targeted delivery of DOX to A549 cells through conjugated folic acid (FA) a self-navigation molecule that docks to the folate receptors on cancer cells. The comprechensive physicochemical, cytotoxicity and genotoxicity studies were performed to characterise the novel QD-based nanocaries and their anticancer cargos. Results The results from FTIR, DLS and fluorescence quenching evidenced the successful attachment of FA to the QDs nanocrystals and DOX to the QDs-FA nanocarriers. UV-vis analysis determined the amount of FA and DOX covalently anchored to the QDs nanocrystal surface. Biological screeining revealed that QDs-FA-DOX nanoconjugates showed higher cytotoxicity in comparison to other forms of the synthesized QD samples, suggesting the cytotoxic effect of liberated DOX from the QD constructs. QD-MUA-FA-DOX occurred to be the most cytotoxic against A549 cells among nanoconjugates. In vitro scratch assay also revealed significant inhibition of A549 migration only due to treatment with QD-MUA-FA-DOX. Studies evidenced that all the nanoconjugates at IC 50 induced significantly more DNA breaks than that observed in non-treated cells. All in all, significant and the greatest cytotoxicity, genotoxicity together with inhibition of migratory potential of A549 cells was observed for QD-MUA-FA-DOX. Conclusion The studies show the therapeutic efficacy of DOX-loaded QD-based cargos suggesting their promising role as novel drug delivery systems navigating to folate receptors in lung cancer cells.


Sign in / Sign up

Export Citation Format

Share Document